

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **KIRSCHNING et al.**
PCT App. No.: **PCT/EP2004/010700**
Serial No.: **10/595,204**
Filing/371 Date: **Mar. 23, 2006**
For: **TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF**
Group: **1647**
Examiner: **Bridget E. Bunner**
Confirmation No. **4608**

**RESPONSE TO NOTICE TO COMPLY, AMENDMENT AND
SEQUENCE STATEMENT**

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Notice to Comply mailed July 23, 2009, please enter the following Amendment in the application and consider the following remarks.

Amendments to the Specification begin on page **2** of this paper.

Amendments to the Claims begin on page **4** of this paper

Remarks/Arguments/Sequence Statement begin on page **9** of this paper.

CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. § 1.8			
I hereby certify that this correspondence, including any items indicated as attached or included, is being transmitted via electronic transmission via EFS-Web on the date indicated below.			
Name of Person Signing	David W. Maher		
Signature	/David W. Maher/	Date	9/23/09